Erasure and reestablishment of random allelic expression imbalance after epigenetic reprogramming

AARON RICHARD JEFFRIES,1,2 DAFE AGHOOGHO UWANOGHO,2 GRAHAM COCKS,2 LEO WILLIAM PERFECT,2 EMMA DEMPSTER,1 JONATHAN MILL,1,2,3 and JACK PRICE2,3

1University of Exeter Medical School, University of Exeter, Exeter EX2 5DW, United Kingdom
2Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, United Kingdom

ABSTRACT

Clonal level random allelic expression imbalance and random monoallelic expression provides cellular heterogeneity within tissues by modulating allelic dosage. Although such expression patterns have been observed in multiple cell types, little is known about when in development these stochastic allelic choices are made. We examine allelic expression patterns in human neural progenitor cells before and after epigenetic reprogramming to induced pluripotency, observing that loci previously characterized by random allelic expression imbalance (0.63% of expressed genes) are generally reset to a biallelic state in induced pluripotent stem cells (iPSCs). We subsequently neuralized the iPSCs and profiled isolated clonal neural stem cells, observing that significant random allelic expression imbalance is reestablished at 0.65% of expressed genes, including novel loci not found to show allelic expression imbalance in the original parental neural progenitor cells. Allelic expression imbalance was associated with altered DNA methylation across promoter regulatory regions, with clones characterized by skewed allelic expression being hypermethylated compared to their biallelic sister clones. Our results suggest that random allelic expression imbalance is established during lineage commitment and is associated with increased DNA methylation at the gene promoter.

Keywords: RNA; allelic expression; DNA methylation; stem cells; monoallelic; iPSC

INTRODUCTION

Although autosomal genes are predominantly expressed from both the maternal and paternal alleles, examples of allelic imbalance or monoallelic expression have been described. Genotype-associated allelic imbalances, regulated by expression quantitative trait loci (eQTLs) in cis, are acknowledged to be a widespread source of phenotypic variation in humans (Ge et al. 2009) and mouse (Crowley et al. 2015). Monoallelic expression can also be epigenetically controlled in a parent-of-origin specific manner, as exemplified by genomic imprinting (Reik and Walter 2001), a relatively rare phenomenon affecting approximately 100 genes in human and 120–180 genes in mouse (Babak et al. 2015; Crow et al. 2015). Monoallelic expression can also be epigenetically controlled in a parent-of-origin specific manner, as exemplified by genomic imprinting (Reik and Walter 2001), a relatively rare phenomenon affecting approximately 100 genes in human and 120–180 genes in mouse (Babak et al. 2015; Crow et al. 2015). Monoallelic gene expression can also be random, whereby a cell stochastically expresses a single allele. This phenomenon has been well described in female mammalian cells, which transcriptionally inactivate the majority of genes on one randomly chosen X chromosome (Lyon 1986; Carrel and Willard 2005). X-chromosome inactivation occurs during the morula to blastocyst stage and is epigenetically maintained during subsequent mitotic cell divisions (Deng et al. 2014). Autosomal genes can also undergo random monoallelic expression, with initial descriptions of its occurrence in immune genes (Mostoslavsky et al. 2001) and the olfactory receptors (Chess et al. 1994), providing cellular diversity within these systems. Recent high-throughput allelic expression profiling of human clonal lymphoblastoid, fibroblast, and neural stem cells has shown that stochastic allelic expression is more prevalent than previously thought, affecting up to 10% of autosomal expressed transcripts across a diverse range of cell types (Gimelbrant et al. 2007; Chess 2012; Jeffries et al. 2012; Li et al. 2012; Zwemer et al. 2012). This process has also been observed in mouse, with a significant overlap in loci characterized by random monoallelic expression across species (Zwemer et al. 2012). The cellular diversity resulting from such stochastic monoallelic gene expression is likely to result...
in considerable clonal level phenotypic heterogeneity within tissues.

Although complex multiple-promoter regulated expression drives the stochastic process of allelic choice in a limited number of genes, for example the immune gene Ly49 and the protocadherin clusters alpha and gamma (Ensminger and Chess 2004; Chess 2005), the mechanisms driving most cases of autosomal random monoallelic expression are not known. It has been shown that while biallelic genes are synchronously replicated in S-phase, random monoallelically expressed genes show asynchronous replication, even before the activation of transcription (Kitsberg et al. 1993; Simon et al. 1999).

Epigenetic processes such as DNA methylation and histone modifications are also associated with this form of transcriptional control (Jeffries et al. 2012; Nag et al. 2013). While increased DNA methylation at the gene promoter is associated with monoallelic gene expression (Gendrel et al. 2014), DNA methylation on its own may not be sufficient for allelic expression control (Eckersley-Maslin et al. 2014; Gendrel et al. 2014).

Stochastic monoallelic loci are distributed across the genome and encompass most functional gene ontologies, although some studies indicate that they are enriched among cell surface molecules (Gimelbrant et al. 2007; Jeffries et al. 2012). Two recent studies examined the developmental patterns of random monoallelic expression using clonally expanded embryonic stem cells (ES) and neural progenitor cells from outcrossed mice (Eckersley-Maslin et al. 2014; Gendrel et al. 2014). Approximately 0.5% of transcribed genes in ES cells were characterized by random monoallelic expression, compared to 2%–3% of expressed genes in derived neural progenitor cells. There was little overlap in the specific monoallelic genes between ES cells and neural progenitor cells, although there was overlap between the neural progenitor cells from the two studies (Eckersley-Maslin et al. 2014; Gendrel et al. 2014; Reinius and Sandberg 2015). Allelic expression has also been examined in human fibroblasts reprogrammed into induced pluripotent stem cells (iPSCs) (Tanaka et al. 2013). A bias or allelic preference was observed in a subset of genes during the intermediate stage of reprogramming, with biallelic expression restored when iPSC reprogramming is complete.

In this study, we examined the effects of epigenetic reprogramming on allelic expression decisions within a defined clonal human neural progenitor cell line. We first quantified the extent of random monoallelic expression and related this to DNA methylation in fetal-derived clonal neural progenitor cells. Subsequently, we assessed allelic patterns of gene expression after epigenetic reprogramming into a pluripotent state (Takahashi and Yamanaka 2006). Finally, the resulting iPSCs were committed back into a neural lineage, and clonal neural stem cells subsequently profiled. We show, for the first time in human cells, the dynamic nature of allelic expression patterns across pluripotent and lineage committed states.

RESULTS
Epigenetic reprogramming to induced pluripotency resets random allelic expression imbalance

To investigate the effect of epigenetic reprogramming to induced pluripotency on stochastic allelic expression, we profiled allelic expression patterns in three conditionally immortalized clonal human neural stem cells (proliferative state: SPC01, SPC04, and SPC06; and differentiated state: SPC01D, SPC04D, and SPC06D) and reprogrammed iPSC clones derived from one of these (SPC01). Two iPSC clones were profiled (iPS1 and iPS2) at “early” (6–10 passages) and “late” (20–22 passages) passages (see Supplemental Fig. S1 for an overview of our experimental design). Approximately 7000 autosomal genes contained informative (heterozygous) transcribed SNPs (see Materials and Methods) allowing us to make quantitative allelic expression measurements. Based on previous allelic expression studies (Pasticen et al. 2004; Serre et al. 2008; Lee et al. 2009; Jeffries et al. 2012) and X-chromosome inactivation profiles (Supplemental Fig. S2), we categorized the expression of genes as biallelic (BA), allele-specific imprinted. By examination of the two sister clones for autosomal MA-expressed genes, not known to be genomically imprinted. By examination of the two sister clones for alternative allelic expression profiles, we conservatively estimate that 23 (29% of SPC01 expressed MA genes) show evidence of random allele expression imbalance based on differing allelic expression profiles in sister clones. Our subsequent analyses focused primarily on the representative clone SPC01, which was characterized by 79 autosomal MA-expressed genes, not known to be genomically imprinted. By examination of the two sister clones for alternative allelic expression profiles, we conservatively estimate that 23 (29% of SPC01 expressed MA genes) show evidence of random allele expression imbalance. After epigenetic reprogramming to induced pluripotency, 20 of these random allele expression imbalanced genes were expressed at detectable levels in the resultant iPSC clones. Strikingly, 17 (85%) of these initial random allele expression imbalanced loci showed clear BA expression after reprogramming (Table 1B; Fig. 1A). Allelic expression measurements were successfully validated by single nucleotide primer extension.
assays at all loci tested (Fig. 1B). While reprogramming involves a number of cell signaling pathways, the widespread epigenomic changes that occur during reprogramming (Koche et al. 2011; Polo et al. 2012) give support toward a role for epigenetic processes regulating random allelic expression imbalance.

An additional 56 MA gene loci detected in the SPC01 cell line could not be unequivocally identified as being characterized by random allelic expression imbalance because either the same allele was expressed in all three sister clones or expression was not reliably detected in all clones (see Fig. 1C). Examining their response to reprogramming revealed that

### TABLE 1. Summary of allelic expression profiles for the clonal cell lines in this study

| (A) Clonal neural stem cells | Total genes with allelic expression measurements | MA genes (including imprinted) | MA genes (excluding known imprinted genes) | Random allelic expression imbalanced genes | Number of technical replicates |
|-----------------------------|-----------------------------------------------|-------------------------------|---------------------------------------------|------------------------------------------|-------------------------------|
| SPC01/SPC04/SPC06          | 7312                                          | 149                           | 138                                         | 46                                       | 3                             |
| SPC01D/SPC04D/SPC06D        | 7523                                          | 114                           | 100                                         | 39                                       | 3                             |

| (B) Before epigenetic reprogramming |
|-----------------------------------|
| SPC01                             | 6531                                          | 90                            | 79                                          | 23                                       | 3                             |
| SPC01 differentiated 2 wk          | 6997                                          | 58                            | 46                                          | 16                                       | 3                             |

| (C) After epigenetic reprogramming of SPC01 |
|---------------------------------------------|
| iP1 early passage                          | 7259                                          | 55                            | 48                                          | 3                                        |
| iP1 late passage                           | 7333                                          | 52                            | 45                                          | 3                                        |
| iP2 early passage                          | 6930                                          | 31                            | 24                                          | 2                                        |
| iP2 late passage                           | 7303                                          | 43                            | 36                                          | 3                                        |

| (D) Clonal neural stem cells from iPSC clones 1 and 2 |
|------------------------------------------------------|
| NSC1a/NSC1b/NSC1c                                   | 7122                                          | 75                            | 66                                          | 24                                       | 2                             |
| NSC2a/NSC2b                                         | 7176                                          | 105                           | 96                                          | 8                                        | 1                             |
| NSC2 polyclonal                                     | 7391                                          | 37                            | 29                                          | -                                        | 1                             |

| (B) iPSC BA MA AS MA and BA NE |
|-------------------------------|
| SPC01 RAI                     | 23                                            | 17                            | 1                                           | 1                                        | 3                             |
| SPC01 MA                      | 56                                            | 26                            | 20                                          | 5                                        | 0                             |

| (C) SPC01 MA BA AS NE |
|----------------------|
| iPSC MA              | 68                                              | 22                            | 23                                          | 8                                        | 15                            |

| (D) NSC1 - 66 monoallelic genes |
|---------------------------------|
| MA BA AS NE                     |
| iP1 early                       | 11                                              | 35                            | 5                                           | 15                                       |
| iP1 late                        | 11                                              | 35                            | 6                                           | 14                                       |
| SPC01                           | 13                                              | 26                            | 7                                           | 20                                       |

| (D) NSC2 - 96 monoallelic genes |
|---------------------------------|
| MA BA AS NE                     |
| iP2 early                       | 10                                              | 38                            | 6                                           | 42                                       |
| iP2 late                        | 12                                              | 40                            | 5                                           | 39                                       |
| SPC01                           | 14                                              | 21                            | 6                                           | 55                                       |

(A) Result summaries are shown for SPC01, SPC04, and SPC06 at proliferative and differentiated (denoted by “D”) states. Separate counts for SPC01 are also shown since this was epigenetically reprogrammed and two induced pluripotent stem cells isolated (iPS1 and iPS2), collected at early and late passages. Subsequent lineage commitment to a series of iPS-derived clonal neural stem cells is also shown (NSC1a 1b and 1c derived from iPS1 and NSC2a and 2b from iPS2). A polyclonal cell line is also shown derived from iPS2. The values shown indicate the total number of genes assessed, the number of loci characterized by at least one clone with MA expression, and the number of loci showing random allelic expression imbalanced genes. The number of technical replicates for each cell line is also shown.

(B) Random allelic imbalanced (RAI) and other monoallelic genes (MA) observed in SPC01 and their allelic status after epigenetic reprogramming into iPSCs. Allelic skewing (AS), nonexpressed genes (NE), and iPSC-based gene expression with alternate MA and BA in each clone (MA & BA) are also shown.

(C) How the 68 monoallelic genes detected in both iPSC clones (see main text) are represented in SPC01 prior to reprogramming.

(D) Two tables showing how monoallelic gene expression detected in iPSC-derived NSC clones are represented in their corresponding iPSC clones as well as the original SPC01 prior to reprogramming.
26 of the 56 genes (46%) reverted to BA expression in the iPSCs (Table 1B), while the remaining 30 transcripts were characterized by stable MA expression (20 genes/36%), allelic skewing (five genes/9%), or no detectable expression (five genes/9%) after epigenetic reprogramming. Therefore, the remodeling of epigenetic marks during reprogramming to a pluripotent developmental state appears to erase the MA expression status of most random allelic expression imbalanced genes and ∼50% of the additional 56 MA expressed genes that are likely to contain additional random allelic expression imbalanced genes. The genes that remain MA after reprogramming are likely to represent loci showing a resistance to epigenetic reprogramming (Chen et al. 2013a) or examples of genetically driven MA expression—i.e., cis-acting expression quantitative trait loci (eQTLs) (Ge et al. 2009). To investigate this further, we cross-referenced these genes to loci characterized by aberrant gene expression in iPS cells (Chin et al. 2009) and found no overlap. We also checked 841 genes mapping to known hotspots of aberrant epigenetic reprogramming defined by DNA methylation differences between iPSCs and embryonic stem cells (Lister et al. 2011). Five of these genes (DPP6, FTCD, HEATR4, LRRC61, and MYH14) were present in our list of 22 constant MA expressed genes. This represents about twice as many genes as would be expected by chance but does not represent a statistically significant enrichment (two-tailed Fisher’s exact test P-value = 0.41). From this, we conclude that it is likely that the majority of MA expressing genes that fail to respond to the reprogramming actually represent examples of genetically driven MA expression.

We also examined an additional 23 random allelic expression imbalanced genes, characterized by BA expression in the SPC01 cell line but MA expression in either of the sister clonal lines (SPC04 or SPC06). Of these genes, 20 showed measurable expression in the iPS state, all with biallelic expression except NLRP2, which showed random allelic expression imbalance. After neuralization, the majority of the genes maintained BA expression apart from NLRP2, which showed MA expression, and SYT3, which was characterized by skewed allelic expression in two neural stem cell clones.

Of the 68 genes (0.88% total genes assayed) characterized by MA expression in at least one iPSC clone (iPS1 early and late passage clones = 62 genes, iPS2 early and late passage clones = 39 genes, overlap between two iPSC clonal sets = 33 genes). Of these, 22 genes were characterized as being MA in the original SPC01 cell line before reprogramming, suggesting that their allelic expression status is resistant to epigenetic reprogramming or influenced by cis-acting genetic factors. The remaining 46 genes (0.59% of total genes assayed) potentially indicate de novo MA expression

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Changes in allelic expression are seen across different developmental states. (A) Allelic expression profiles for genes identified as monoallelically expressed in the SPC01 neural stem cell. Allelic expression is shown for SPC01, SPC04, and SPC06 at proliferative and differentiated states (denoted with “D”) as well as its resulting IPS clones at early and late passage (labeled “Early” and “Late”), together with iPS-derived clonal NSC’s and a polyclonal cell isolate (labeled “pc”). Genes have been categorized into two groups—those positively identified as showing random allelic expression imbalance and those which only show MA expression in measured clones. The abbreviation SK indicates genes showing allelic skewing. (B) Validation of the resetting of monoallelic expression detected in SPC01 to a more biallelic form of allelic expression in iPSC clones. The percentage expression of the major expressed allele is shown in relation to the highlighted regions indicating monoallelic and biallelic expression. “S” denotes the SNAPshot primer extension assay results and “A” denotes the allelic expression results from the Illumina beadchip. (C) MA genes found in the epigenetically reprogrammed iPSCs. (D) MA genes identified in the iPSC-derived neural stem cells. See Supplemental Figure S3 for high-resolution heatmaps.

---

**Novel monoallelic gene expression in reprogrammed iPSCs**

Allelic expression profiling of the two iPSC clones at early and late passage identified 68 genes (0.88% total genes assayed) characterized by MA expression in at least one iPSC clone (iPS1 early and late passage clones = 62 genes, iPS2 early and late passage clones = 39 genes, overlap between two iPSC clonal sets = 33 genes). Of these, 22 genes were characterized as being MA in the original SPC01 cell line before reprogramming, suggesting that their allelic expression status is resistant to epigenetic reprogramming or influenced by cis-acting genetic factors. The remaining 46 genes (0.59% of total genes assayed) potentially indicate de novo MA expression.
Neuralization reestablishes random allelic expression imbalance

The majority (85%) of random allelic expression imbalanced genes identified in the original SPC01 neural stem cell lines reverted to BA expression after epigenetic reprogramming to induced pluripotency. To explore what happens when these iPSCs are recommitted to a more restricted neural progenitor cell lineage, we neutralized two iPSC clones using a dual SMAD inhibition method (see Materials and Methods) to produce rosette-like neural stem cells (Chambers et al. 2009). We subsequently sequenced cDNA for previously identified random allelic expression imbalanced genes, identifying BA expression signatures in the iPSC-derived neural stem cells (Supplemental Fig. S4) as would be expected since this population of neural cells is polyclonal, derived from multiple individual neuralized cells.

We subsequently isolated clonal cell lines by dilution plating of this polyclonal population, and cultured the surviving colonies to sufficient density for RNA isolation and profiling. Five neural stem cell clones were isolated in total (three from one iP51 clone [termed NSC1] and two from a second iP52 clone [termed NSC2]) in addition to the polyclonal population sample. Approximately 7100 genes were informative for allelic expression profiling, of which 66 (0.93% of total assayed genes) were identified as being characterized by MA expression in at least one of the NSC1 clones. Ninety-six MA-expressed genes (1.34% of total assayed genes) were identified in the NSC2 clone set, although the lack of a technical replicate in this latter set may be one reason for the higher call rate. Examining the overlap between clone sets, 37 (58.7%) of 63 genes expressed in both clonal sets showed evidence of MA expression in both NSC1 and NSC2 clones. Most of these NSC1 and NSC2 genes represent novel MA loci and were not characterized by MA expression in the original SPC01 line. The limited gene ontology analyses we could undertake given the small number of input loci provided evidence for an overrepresentation of proteins integral to the plasma membrane (GO:0005887, P = 0.04, 1.97-fold enrichment), reflecting the patterns seen in the original clonal neural stem cell before reprogramming in addition to neural stem cells from other brain regions (Jeffries et al. 2012) and clonal lymphoblastoid cells (Gimelbrant et al. 2007).

Using the clonal results, we estimated the frequency of random allelic expression imbalance identifying alternate allelic expression patterns across clones. Individually, 24 random allelic expression imbalanced genes were identified in the NSC1 clones (36.4% of total MA genes identified within the three clones) and eight in NSC2 (8.3% of total MA genes from two clones). Combining NSC1 and NSC2 to give five clones showed 7334 total genes expressed, with 126 genes (1.71%) showing at least one clone with MA expression and 48 of these (0.65% of total expressed genes) displaying random allelic expression imbalance. An alternate approach to estimate the frequency of random allelic expression imbalance is to examine a polyclonal population in combination with clonal cells. Since random allelic expression imbalance choice appears to be a stochastic process, measurements in polyclonal populations are expected to show approximately equal quantities of both alleles, i.e., apparent BA expression. We found that 42 of the 48 (88%) random allelic expression imbalanced genes identified in the five clones of NSC1 and NSC2 were characterized by a BA signal when examined in polyclonal neural stem cells. The polyclonal neural stem cell showed measurable expression for 88 of the 126 MA expressed genes identified in the NSC1 and NSC2 clones. From these, 62 genes (70.5%) were characterized by BA expression in the polyclonal cell line, indicating a higher frequency of 0.84% of total expressed genes showing random allelic expression imbalance frequency compared to our estimate of 0.65% using clonal lines alone. Seventeen genes were also identified as being MA expressed (19.3%) in the polyclonal line, with nine genes with allelic skewing (10.2%), presumably influenced by cis-acting genetic effects. Based on our data, we conclude that lineage commitment commits approximately 1.7% of genes to MA expression, of which between 0.65% and 0.84% of expressed genes are characterized by random allelic expression imbalance.

DNA methylation correlates with allelic status

Global patterns of DNA methylation (Fig. 2A,B) show only modest changes associated with developmental state, although we observe large changes in DNA methylation at specific CpG sites; 40,425 CpGs of 415,863 were characterized by >30% (\(\Delta\beta > 0.3\)) differences in DNA methylation between SPC01
and iPSCs before and after reprogramming. Increased levels of non-CpG site DNA methylation were also found during the pluripotent iPSC stage (Fig. 2C,D) compared to neural stem cells before and after reprogramming. Hierarchical clustering based on CpG and non-CpG sites distinguished the different clonal developmental states used in this study (Fig. 2E,F). Overall, the DNA methylation changes described are in agreement with expected changes reported from a previous study examining multiple tissue types and their reprogrammed pluripotent counterparts (Nishino et al. 2011).

Building on our previous evidence for increased levels of DNA methylation associated with random MA expressed genes (Jeffries et al. 2012), we compared DNA methylation in iPSC-derived NSC clones showing MA expression to clones showing BA expression, identifying dramatic differences at numerous loci. For example, TNFRSF10D, which we previously reported as showing random allelic expression imbalance (Jeffries et al. 2012), is significantly hypomethylated in reprogrammed iPSC compared to the MA expressing SPC01 cell line across all probes associated with an exon spanning CpG island (average DNA methylation difference = 19.9%, paired $t$-test $P$-value = 0.015) (Supplemental Fig. S6). Lineage commitment associated with skewed allelic expression is characterized by increased DNA methylation at this locus, whereas a clone with no detectable expression is characterized by even higher DNA methylation levels.

Overall, three broad classes of genic region were characterized by differences in DNA methylation within MA expressing clones compared to BA clones (Fig. 3; Supplemental Table S1). Increased DNA methylation was found in MA expression clones at regions $\sim 200$ bp upstream of the transcriptional start site (paired Wilcoxon rank sum test $P$-value = 0.006), indicative of differential methylation at the gene promoter, and similar increased expression at the first exon (paired Wilcoxon rank sum test $P$-value $= 3.726 \times 10^{-7}$). The gene body, in contrast, showed decreased DNA methylation in MA expressing clones (paired Wilcoxon rank sum test $P$-value $= 0.003458$). These observations of increased DNA methylation at the promoter and decreased levels within the gene body are interesting given the repressed transcriptional activity of MA expressed genes (Jones 2012). We also examined DNA methylation across annotated CpG island features. CpG island shelves and shores showed no statistically significant difference. However, more dramatic differences in DNA methylation were observed within actual CpG islands, with significantly increased DNA methylation associated with MA expression (paired Wilcoxon rank sum test $P$-value $= 4.799 \times 10^{-10}$).

Previous studies have also shown an association with other epigenetic signatures (Jeffries et al. 2012; Nag et al. 2013).
ES cells showing higher levels than their neural progenitor counterparts compared to H9 neural progenitors showing higher levels than their original ES cell status (Wilcoxon rank sum P-value <2.2 × 10^{-16}). No differences were observed at DNase I hypersensitivity sites (Wilcoxon rank sum P-value = 0.78).

**DISCUSSION**

The aim of this study was to assess the effects of induced pluripotency on genes characterized by random allelic expression imbalance. We show that the majority of random allelic expression imbalanced genes with initial MA expression were reset to a BA status when reprogrammed. After lineage commitment back into a neural stem cell state, MA expression was reestablished in some of the original MA genes, in addition to many new genes that had been BA-expressed prior to reprogramming. We also observed some de novo MA expression arising in the iPSC clones, perhaps representing partial commitment to random allelic expression imbalance or simply reflecting a dynamic allele-specific transcriptome. Similar de novo allelic expression bias was also noted in another study examining human iPSC reprogramming stages (Tanaka et al. 2015) and murine ES cells (Eckersley-Maslin et al. 2014; Gendrel et al. 2014).

The primary cause of monoallelic expression was originally thought to be through genomic rearrangements based on early cloning experiments of mature lymphocytes which resulted in monoclonal mice containing the same rearranged t-cell receptor gene in all tissues (Hochedlinger and Jaenisch 2002). However, nuclear transfer experiments of post-mitotic olfactory neurons proved otherwise, showing allelic expression status was reset upon nuclear transfer (Eggan et al. 2004; Li et al. 2004) resulting in cloned mice with a full repertoire of olfactory receptors. Our experiment builds on this and shows widespread resetting of monoallelic expression in genes undergoing random allelic expression imbalance/random monoallelic expression control after reprogramming to pluripotency. Previous to this work, two papers examining murine ES cells and derived neural progenitor cells detected increased levels of random monoallelic imbalance/random monoallelic expression upon differentiation (0.5% genes in ES cells versus 3% in neural progenitor cells). Our study shows a lower estimate of random allelic imbalanced expression in analogous iPSC cells and human neural progenitor cells, which may reflect the lower number of clones examined.

If the pluripotency and lineage committed results correctly extrapolate in vivo, it suggests allelic expression assignment occurs during either gastrulation or neurulation. An over-representation of genes encoding cell surface/cell membrane proteins was found among the MA-expressing loci, agreeing with previous studies (Gimelbrant et al. 2007; Jeffries et al. 2012). Cell surface diversity may therefore be a factor driven...
by random allelic expression imbalance, allowing alternate isoforms that may encode functional differences to be expressed in a subset of cells. This process would also provide a mechanism to support dosage variation, a phenomenon previously associated with monoallelic expression (Gimelbrant et al. 2007; Jeffries et al. 2012; Li et al. 2012). This may have profound implications for tissues such as the brain where cell identity and cell migration are highly dependent on receptor–ligand or receptor–morphogen interactions. As previously hypothesized, it may also contribute to disease discordance observed in monozygotic twin-pairs (Jeffries et al. 2013; Oey et al. 2015).

Recent single cell gene expression analyses have shown evidence for widespread monoallelic expression, although this is often dynamic in nature, presumably from the stochastic burst-like nature of transcription (Reinius and Sandberg 2015). However, mitotically stable random monoallelic expression (and allelic expression imbalance), as detected in clonal cell line studies such as in this study, is more likely mediated by epigenomic modifications. We and others find differential promoter level DNA methylation, a reduction of active chromatin signatures and increased repressive histone modifications associated with many random monoallelic expressed loci (Jeffries et al. 2012; Eckersley-Maslin et al. 2014; Gendrel et al. 2014). However, use of 5-azacytidine to deplete cells of DNA methylation marks failed to alter MA expression in examined candidate genes (Eckersley-Maslin et al. 2014; Gendrel et al. 2014). This observation has some similarities to a study in mouse embryonic fibroblasts which examined imprinted genes after 5-azacytidine exposure (El Khouroubi et al. 2001). Exposure altered allelic expression in some imprinted genes but failed to have an impact on other imprinted gene loci (El Khouroubi et al. 2001), indicating differences in allelic regulation mechanisms between some of the imprinted MA expressed genes. It is uncertain whether random monoallelic expressed genes throughout the genome are regulated in the same way or have differences in control mechanisms. Regardless, these data indicate that an additional layer of epigenetic control, such as histone tail modifications or antisense RNA, may play a role in regulating monoallelic expression.

In conclusion, we provide evidence to support the notion that random or stochastic MA expression is a form of transcriptional control, which is set early in development during lineage commitment. The reprogramming of cells to an embryonic stem-cell-like state erases this form of transcriptional control but directed commitment to a neural stem cell lineage promotes its reassignment at a number of genes. Specific loci may show an inherent susceptibility to random allelic expression imbalance, with genes encoding cell surface molecules being particularly affected by this form of transcriptional control. Increased DNA methylation at the gene promoter, particularly across CpG Islands, is associated with monoallelic expressing clones and may play a key role in maintaining the repression of the inactive allele.

**MATERIALS AND METHODS**

**Cell culture and derivation of induced pluripotent stem cells and neural stem cells**

Conditionally immortalized human neural stem cell lines were derived from 10-wk-old fetal cervical spinal cord as described in Cocks et al. (2013). Three clones were used in this study (SPC01, SPC04, and SPC06) in their proliferative state, or following 2 wk of neural differentiation in culture (SPC01D, SPC04D, and SPC06D), which gives rise to a population of neurons and glia. The SPC01 cell line was epigenetically reprogrammed using a lentiviral vector to express OCT4, SOX2, KLF4, and c-MYC. Clones were isolated and pluripotency checked through the gene expression-based PluriTest (Müller et al. 2011) and immunocytochemistry for the pluripotency markers (Supplemental Fig. S9). Two iPS clones were carried forward in this study (iPS1 and iPS2), with early (6–10) and late (20–22) passage clones collected for analysis. Neural stem cells were also derived from the two iPSC clones using a dual SMAD inhibition procedure as described by Chambers et al. (2009). Clones were isolated through serial dilution into 96-well plates of single cells followed by expansion up to six-well plates for RNA and DNA harvesting. Expansion and subsequent profiling of two replicate wells was possible with NSC1 clones, although only one well was available for the NSC2 clones. This may result in higher incidence of false positives in the NSC2 clones.

**Nucleic acid isolation**

RNA was collected and extracted using TRIzol (Life Technologies) followed by DNase treatment (DNA Turbo free, Life Technologies). DNase-treated RNA quality was assessed with the Agilent Bioanalyzer (RIN > 9) and quantitative PCR on 200 ng of RNA to ensure no remaining genomic DNA. One microgram of RNA was converted to cDNA using random hexamers and Superscript III reverse transcriptase (Life Technologies) at 42°C for 2 h. Genomic DNA was extracted from cell pellets by incubation in sodium chloride-Tris-EDTA buffer containing 0.5% SDS with RNaseA (10 µg/mL) for 45 min at 37°C followed by Proteinase K (0.2 mg/mL) addition and further incubation at 50°C for 120 min. Phenol/chloroform extraction was then performed.

**Allelic expression analysis**

We carried out a genome-wide allelic expression analysis using methods previously described in Jeffries et al. (2012). Briefly, the Illumina HumanOmniExpress-12 SNP beadchip was used to assess allelic expression using 250 ng of genomic DNA and cDNA equivalent of 200 ng of RNA. The resulting cDNA and gDNA results were separately quantile normalized across both channels before analysis. Any probes where the sum of X + Y (representing the scanned intensity for each allele) exceeded 750 were included in the analysis. Those below 750 were excluded as background signal noise. A β value of X/(X + Y) was then calculated to provide a quantitative scale of allelic expression rather than a binary assignment from standard genotyping software. The difference in Δβ value between cDNA measurements versus genomic DNA heterozygous SNPs was then used to calculate allelic expression at SNP probes, and the mean absolute Δβ value of all informative SNPs for RefSeq gene results. Intronic SNPs with sufficient intensity above
background signal were included in the analysis since they also provide accurate allelic expression measurements (Pastinen et al. 2004; Gimelbrant et al. 2007; Serre et al. 2008). Allelic expression assignments were made according to the degree of allelic imbalance detected. MA expression is indicated by a 2.85 or greater difference in allele expression ratios (Δβ > 0.2), allelic expression skewing as a 1.5–2.85 (Δβ > 0.1 and Δβ < 0.2), and biallelic expression (BA) for those genes with a 1.0–1.5 ratio between alleles (Δβ < 0.1). The Δβ SNP probe distribution for autosomes compared to the X chromosome (containing a high number of inactivated/monoallelic expressed genes) is shown in Supplemental Figure S2 and highlights the use of Δβ > 0.2 being an appropriate threshold for MA expression. A penalty weighting score was also applied to minimize bias of large transcripts, described in more detail in Jeffries et al. (2012). Transcript-based analysis was performed in an isof orm-specific manner. Known imprinted genes, as identified through genome sequence analyses were carried out using EpiGraph (http://epigraph.mpi-inf.mpg.de). Catalog of imprinted genes (http://geneimprint.com), imprinting (http://geneimprint.com), catalog of imprinted genes (http://geneimprint.com) and a study by Morcos et al. (2011), were excluded from the primary analysis although are described in Supplemental Figure S10. Similarly, chromosome X status is described in Supplemental Figure S11. The α and γ protocadherins were detected as showing random monoallelic expression in this study but were removed from analysis to avoid bias based on their overlapping genome annotations. The lack of a technical cell culture well replicate in the NSC2 set is likely to account for the increased overlapping genome annotations. The lack of a technical cell culture well replicate in the NSC2 set is likely to account for the increased overlapping genome annotations. The lack of a technical cell culture well replicate in the NSC2 set is likely to account for the increased overlapping genome annotations. The lack of a technical cell culture well replicate in the NSC2 set is likely to account for the increased

Validation of allelic expression biases
Single-nucleotide primer extension analysis (SNaPshot, Applied Biosystems) was used to validate allelic expression biases identified using the SNP array. PCR amplification was performed on three genomic DNA samples and three independent reverse transcribed cDNA samples. Four microliters of each PCR reaction were electrophoresed and visualized on agarose gels to confirm specific amplification. Five microliters of PCR reactions were then treated with 1 U shrimp alkaline phosphatase (GE Healthcare) and 2 U Exonuclease I (New England Biolabs) at 37°C for 45 min and then at 85°C for 15 min prior to primer extension reactions. Primer extension reactions were then carried out on the treated PCR products in a total volume of 10 µL containing 2 µL treated PCR product, 1.25 µL SNaPshot reagent (Applied Biosystems), 5.75 µL H2O and 1 PM extension primer. Primer extension thermocycling conditions consisted of an initial step of 95°C for 2 min, followed by 30 cycles of 95°C for 5 sec, 43°C for 5 sec and 60°C for 5 sec. Aliquots of 2 µL SNaPshot reaction product were combined with 8 µL Hi-Di formamide (Applied Biosystems) and electrophoresed on a 3130 Genetic Analyzer (Applied Biosystems). Peak heights of allele-specific extended primers were determined using GeneMarker software (SoftGenetics) and the ratio of the two peak heights calculated for each reaction to determine a β-value similar to the allelic expression assessments from the genome-wide allelic expression profiling.

Epigenetic analysis
For DNA methylation analyses, genomic DNA (500 ng) from each sample was treated in duplicate with sodium bisulfite using the Zymo EZ DNA Methylation-Lightning Kit (Zymo Research). Genome-wide DNA methylation was quantified using the Illumina Infinium HumanMethylation450 BeadChip (Illumina) and scanned on the HiScan System (Illumina). Illumina GenomeStudio software (Illumina) was used to extract signal intensities for each probe, generating a final report that was imported into the R statistical environment 3.0.2 (R Development Core Team 2005) using the methylumi and minfi packages (http://bioconductor.org/packages). Data quality control and preprocessing were performed using the wateRmelon package as described previously (Pidsley et al. 2013). Cross hybridizing probes (Blair and Price 2012; Chen et al. 2013b) were removed from the analysis.

For our analysis of histone modifications and DNase I hypersensitivity sites, data generated from H1 and H9 ES cells as well as H1- and H9-derived neural progenitor cells using ChIP-seq and DNase I hypersensitivity site mapping experiments were derived from release 9 of the preprocessed reference human epigenome database (http://egg2.wustl.edu/roadmap/web_portal/) generated by the NIH Roadmap Epigenomics Mapping Consortium (Roadmap Epigenomics Consortium et al. 2015). The corresponding –log10 Poisson P-values representing gene promoter regions (1000 bp upstream and 500 bp downstream of the transcriptional start site) were obtained from this resource and compared within R using boxplots and Wilcoxon rank sum tests.

SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.

ACKNOWLEDGMENTS
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115439, the resources of which are composed of financial support from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ kind contribution. This work was also supported in part by funding from the Mortimer D. Sackler Foundation. DNA methylation profiling was funded by Medical Research Council grant MR/K013807/ 1 to J.M.

Received January 15, 2016; accepted July 25, 2016.

REFERENCES
Babak T, DeVeale B, Tsang EK, Zhou Y, Li X, Smith KS, Kukurba KR, et al. 2015. Genetic conflict reflected in tissue-specific maps of genomic imprinting in human and mouse. Nat Genet 47: 544–549.

Baran Y, Subramaniam M, Biton A, Tukiainen T, Tsang EK, Rivas MA, Pirinen M, Gutierrrez-Arcelus M, Smith KS, Kukurba KR, et al. 2015.
Jeffries AR, Collier DA, Vassos E, Curran S, Ogilvie CM, Price J. 2013. Random or stochastic monoallelic expressed genes are enriched for neurodevelopmental disorder candidate genes. PLoS One 8: e58093.

Jones PA. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484–492.

Kitsberg D, Selig S, Brandeis M, Simon I, Keshet I, Driscoll DJ, Nicholls RD, Cedar H. 1993. Allele-specific replication timing of imprinted gene regions. Nature 364: 459–463.

Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A, Bernstein BE, Meissner A. 2011. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell 8: 96–105.

Lee JH, Park IH, Gao Y, Li JB, Li Z, Daley GQ, Zhang K, Church GM. 2009. A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet 5: e1000718.

Li J, Ishii T, Feinstein P, Moniaux P. 2004. Odorant receptor gene choice is reset by nuclear transfer from mouse olfactory sensory neurons. Nature 428: 393–399.

Li SM, Valo Z, Wang J, Gao H, Bowers CW, Singer-Sam J. 2012. Transcriptome-wide survey of mouse CNS-derived cells reveals monoallelic expression within novel gene families. PLoS One 7: e31751.

Lin M, Hrabovska A, Pedrosa E, Wang T, Zheng D, Lachman HM. 2012. Allele-biased expression in differentiating human neurons: implications for neuropsychiatric disorders. PLoS One 7: e44017.

Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, et al. 2011. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471: 68–73.

Lyon MF. 1986. X chromosomes and dosage compensation. Nature 320: 313.

Morcos L, Ge B, Koka V, Lam KC, Pocholok DK, Gunderson KL, Montpetit A, Verlaan DJ, Pastinen T. 2011. Genome-wide assessment of imprinted expression in human cells. Genome Biol 12: R25.

Mostoslavsky R, Singh N, Tenzen T, Goldmit M, Gabay C, Elizur S, Qi P, Reubinoff BE, Chess A, Cedar H, et al. 2001. Asynchronous replication and allelic exclusion in the immune system. Nature 414: 221–225.

Müller FJ, Schuld MT, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, et al. 2011. A bioinformatic assay for pluripotency in human cells. Nat Methods 8: 315–317.

Nag A, Savova V, Fung HL, Miron A, Yuan GC, Zhang K, Gimelbrant AA. 2013. Chromatin signature of widespread monoallelic expression. eLife 2: e01256.

Nishino K, Toyoda M, Yamasaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi H, Akutsu H, Umezawa A. 2011. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet 7: e1002085.

Oey H, Isbel L, Hickey P, Ehiab H, Whitelaw E. 2015. Genetic and epigenetic variation among inbred mouse littermates: identification of inter-individual differentially methylated regions. Epigenetics Chromatin 8: 54.

Pastinen T, Sladek R, Gurd S, Salmak A, Ge B, Lapage P, Lavergne K, Villeneuve A, Gaudin T, Brändström H, et al. 2004. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics 16: 184–193.

Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. 2013. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics 14: 293.

Poloni M, Andersen E, Walsh RM, Schwarz BA, Neßger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, et al. 2012. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151: 1617–1632.
R Development Core Team. 2005. *R: a language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.

Reik W, Walter J. 2001. Genomic imprinting: parental influence on the genome. *Nat Rev Genet* 2: 21–32.

Reinius B, Sandberg R. 2015. Random monoallelic expression of autosomal genes: stochastic transcription and allele-level regulation. *Nat Rev Genet* 16: 653–664.

Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, et al. 2015. Integrative analysis of 111 reference human epigenomes. *Nature* 518: 317–330.

Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J, et al. 2007. Strong association of de novo copy number mutations with autism. *Science* 316: 445–449.

Serre D, Gurd S, Ge B, Sinnett D, Harmsen E, Bibikova M, Chudin E, Barker DL, Dickinson T, et al. 2008. Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. *PLoS Genet* 4: e1000006.

Simon I, Tenzen T, Reubinoff BE, Hillman D, McCarrey JR, Cedar H. 1999. Asynchronous replication of imprinted genes is established in the gametes and maintained during development. *Nature* 401: 929–932.

Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663–676.

Tanaka Y, Hysolli E, Su J, Xiang Y, Kim KY, Zhong M, Li Y, Heydari K, Euskirchen G, Snyder MP, et al. 2015. Transcriptome signature and regulation in human somatic cell reprogramming. *Stem Cell Rep* 4: 1125–1139.

Zwemer LM, Zak A, Thompson BR, Kirby A, Daly MI, Chess A, Gimelbrant AA. 2012. Autosomal monoallelic expression in the mouse. *Genome Biol* 13: R10.
Erasure and reestablishment of random allelic expression imbalance after epigenetic reprogramming

Aaron Richard Jeffries, Dafe Aghogho Uwanogho, Graham Cocks, et al.

RNA 2016 22: 1620-1630 originally published online August 18, 2016
Access the most recent version at doi:10.1261/rna.058347.116

Supplemental Material
http://rnajournal.cshlp.org/content/suppl/2016/08/18/rna.058347.116.DC1.html

References
This article cites 51 articles, 6 of which can be accessed free at:
http://rnajournal.cshlp.org/content/22/10/1620.full.html#ref-list-1

Open Access
Freely available online through the RNA Open Access option.

Creative Commons License
This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.

Webinar: Successful microRNA qPCR in challenging samples

To subscribe to RNA go to:
http://rnajournal.cshlp.org/subscriptions

© 2016 Jeffries et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society